Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANTON LEE DUKE

Allopathic & Osteopathic Physicians Pediatrics

NPI
1235108150
CMS profile
853486
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$73.99

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $73.99 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Corium, LLC $58.03 4
PFIZER INC. $15.96 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANTON LEE DUKE

NPI 1235108150 · CMS profile ID 853486

Allopathic & Osteopathic Physicians / Pediatrics

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235108150?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235108150?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235108150?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1235108150?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $73.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.9610/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050420589 CMS
Corium, LLC $11.2110/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978562135 CMS
Corium, LLC $8.8509/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978280641 CMS
Corium, LLC $17.3308/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978280633 CMS
Corium, LLC $20.6406/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978452644 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $107.73 7
PY2020 $13.83 1
PY2022 $153.22 8
PY2023 $73.99 5
PY2024 $55.65 3
PY2025 $38.48 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $62,873.99 1
PY2025 Principal investigator $4,783.76 5
PY2024 Recipient $266,973.11 1
PY2024 Principal investigator $78,051.13 417
PY2023 Principal investigator $100,958.30 218
PY2022 Principal investigator $51,887.94 40
PY2021 Principal investigator $22,703.72 8
PY2020 Principal investigator $245,184.29 32
PY2019 Principal investigator $95,542.65 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

418 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Nielsen BioSciences, Inc. $266,973.11 11/30/2024 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1089388073
Principal investigator 1 GlaxoSmithKline, LLC. $2,667.26 09/06/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127515820
Principal investigator 1 ABBVIE INC. $1,868.75 09/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100739138
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889887
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889892
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889900
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889904
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889909
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889913
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889917
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889922
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889926
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889930
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889934
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889938
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889947
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889951
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889955
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889960
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889964
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889968
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889972
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889976
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889981
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889985
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889994
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127889998
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890002
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890007
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890011
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890015
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890019
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890024
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890028
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890032
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890040
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890044
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890049
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890053
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890057
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890061
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890066
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890070
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890074
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890078
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890087
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127890091
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898611
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898657
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898704
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898750
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898798
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898844
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898890
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898938
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127898983
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899008
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899012
Principal investigator 1 Dermavant Sciences, Inc. $175.88 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899016
Principal investigator 1 Dermavant Sciences, Inc. $175.88 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899063
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899110
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899156
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899203
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899249
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899296
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899344
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899395
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899441
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899487
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899535
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899581
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899627
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899673
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899720
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899767
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899814
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899865
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899911
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127899957
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900004
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900050
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900097
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900105
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900109
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900113
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900152
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900203
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900250
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900264
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900298
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900345
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900391
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900439
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900486
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900532
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900578
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900629
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900675
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900722
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900768
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900814
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900861
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900908
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900955
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901001
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901048
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901074
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901096
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901143
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901190
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901236
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901283
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901330
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901376
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901423
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901470
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901521
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901567
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901614
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901661
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901707
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901754
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901801
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901848
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901894
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901941
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127901993
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902039
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902086
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902133
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902180
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902227
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902273
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902319
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902366
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902413
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902464
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902511
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902558
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902605
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902652
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902698
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902745
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902792
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902839
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902877
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902924
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127902970
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903017
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903063
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903097
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903102
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903114
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903161
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903207
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903254
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903305
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903352
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903398
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903445
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903491
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903538
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903586
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903632
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903674
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903678
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903686
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903690
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903694
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903699
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903744
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903791
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903838
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903885
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903931
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127903977
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904027
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904074
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904121
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127904168
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911668
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911672
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911676
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911681
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911685
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911689
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911694
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911698
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911706
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911711
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911715
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911719
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911724
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911728
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911732
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911736
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911741
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911745
Principal investigator 1 Dermavant Sciences, Inc. $200.06 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911753
Principal investigator 1 Dermavant Sciences, Inc. $200.06 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911758
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911762
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911766
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127911770
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915325
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915329
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915338
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915342
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915347
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915351
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915355
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915359
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915364
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915369
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915373
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915377
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915386
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915390
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915395
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915399
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915403
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915407
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915411
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915416
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915420
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915425
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915433
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915438
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915442
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915446
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915450
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915455
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915459
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915463
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915468
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915472
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915481
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915485
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915489
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915493
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915498
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915502
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915506
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915511
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915515
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915519
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915528
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127915533
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924068
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924115
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924163
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924210
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924258
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924304
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924350
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924396
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924443
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924468
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924472
Principal investigator 1 Dermavant Sciences, Inc. $175.88 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924476
Principal investigator 1 Dermavant Sciences, Inc. $175.88 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924523
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924569
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924616
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924662
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924709
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924755
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924803
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924854
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924900
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924946
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127924992
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925038
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925085
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925131
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925177
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925224
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925271
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925321
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925368
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925414
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925460
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925508
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925555
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925563
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925567
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925571
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925610
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925661
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925707
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925719
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925753
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925799
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925846
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925892
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925940
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925987
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926034
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926085
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926131
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926178
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926225
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926272
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926319
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926367
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926414
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926460
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926507
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926533
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926554
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926601
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926648
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926695
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926744
Principal investigator 1 Dermavant Sciences, Inc. $153.75 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926789
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926836
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926883
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926929
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127926979
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927027
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927074
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927122
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927169
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927216
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927264
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927312
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927360
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927406
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927457
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927504
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927550
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927597
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927644
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927691
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927737
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927784
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927831
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927877
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927929
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127927975
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928021
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928068
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928115
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928162
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928209
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928256
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928302
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928341
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928388
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928434
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928481
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928528
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928562
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928566
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928579
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928625
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928671
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928717
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928768
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928815
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928861
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928907
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127928954
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929002
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929049
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929095
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929138
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929142
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929150
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929155
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929159
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929163
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929210
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929258
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929305
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929352
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929398
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929445
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929496
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929541
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929587
Principal investigator 1 Dermavant Sciences, Inc. $153.94 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127929633
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937135
Principal investigator 1 Dermavant Sciences, Inc. $180.19 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937139
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937143
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937147
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937152
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937156
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937160
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937165
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937173
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937178
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937182
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937186
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937190
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937195
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937199
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937203
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937208
Principal investigator 1 Dermavant Sciences, Inc. $33.66 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937212
Principal investigator 1 Dermavant Sciences, Inc. $200.06 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937221
Principal investigator 1 Dermavant Sciences, Inc. $200.06 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937225
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937229
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937233
Principal investigator 1 Dermavant Sciences, Inc. $148.69 08/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127937238
Principal investigator 1 Dermavant Sciences, Inc. $180.19 07/23/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879651
Principal investigator 1 Dermavant Sciences, Inc. $153.94 07/23/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879655
Principal investigator 1 Dermavant Sciences, Inc. $153.94 07/23/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879660
Principal investigator 1 Dermavant Sciences, Inc. $180.19 07/23/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879664
Principal investigator 1 Dermavant Sciences, Inc. $153.75 07/23/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879668
Principal investigator 1 Dermavant Sciences, Inc. $153.94 07/23/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879672
Principal investigator 1 ABBVIE INC. $244.38 07/03/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100725792
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 05/04/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877651
Principal investigator 1 ABBVIE INC. $1,835.00 04/04/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100711472
Principal investigator 1 ABBVIE INC. $5,000.00 04/04/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100711474
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 03/15/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876487
Principal investigator 1 Dermavant Sciences, Inc. $871.25 03/15/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876491
Principal investigator 1 ABBVIE INC. $244.38 03/07/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100706774
Principal investigator 1 Dermavant Sciences, Inc. $872.31 03/02/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127876033
Principal investigator 1 Dermavant Sciences, Inc. $872.31 01/17/2024 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127875327